GNT Pharma Announces Approval of IND Application for the Phase III RODIN Trial of Nelonemdaz for Acute Ischemic Stroke Patients

YONGIN, South Korea, Sept. 8 (Korea Bizwire) – GNT Pharma Inc. today reported that the Korea Ministry of Food and Drug Safety (MFDS) has approved the Investigational New Drug Application (IND) for a phase III study of nelonemdaz for acute ischemic stroke patients (RODIN trial). The IND approval for a more extensive phase III trial is [...]